Patent Application
20080227988
This invention relates to a method of crystallisation and purification of the anti-muscarinic drug glycopyrronium bromide.
Glycopyrronium bromide (Glycopyrrolate, US Pharmacopeia) is the higher melting (193.2° C.-194.5° C.) of two possible diastereoisomeric racemates, i.e. the erythro racemate. Glycopyrronium bromide is manufactured by the method disclosed in U.S. Pat. No. 2,956,062, utilizing N-methylpyrrolidin-3-ol (NMP) and methyl hydroxycyclopentylmandelate (MCPM), as follows:
The initial product from the methylation reaction in methyl ethyl ketone (MEK; stage 3) is isolated as an approximately 50:50 mixture of the two possible pairs of diastereoisomers. In order to obtain the desired drug, i.e. the racemic mixture of the R, S and S, R pair of diastereoisomers, the R, R/S, S pair is removed by recrystallising the crude product from a mixture of methanol and MEK.
In the established manufacturing process, there is no provision to control the particle size of the drug substance. The large and inconsistent particle size produces a physically unstable drug substance following micronisation. Material is difficult to formulate into a drug product suitable for inhalation.
Further, apart from controlling the melting point, the US Pharmacopeia makes no provision for the determination of the amount of the R, R and S, S diastereoisomeric pair in the active pharmaceutical ingredient.
Commercially available MCPM may contain high levels of impurities. These impurities react competitively in stage 2, to produce high levels of carried through impurities in glycopyrronium base, and then in the final salt.
This invention relates to the production of glycopyrronium bromide utilising a novel crystallization process (Stage 3 in scheme 1). In addition to high purity, a consistent and fine particle size is controlled by the solvent, e.g. a solvent of the formula R1COR2 or R1COOR2 wherein R1 and R2 are each alkyl of 1 to 8 C atoms. In addition, the process preferably comprises also a slow cooling rate in the final crystallization steps. The particle size of glycopyrronium bromide produced by this method ensures a physically stable micronised drug substance that is suitable for formulation into a drug product optimized for inhaled delivery.
In a preferred embodiment of the invention, carrying out the methylation reaction in acetone ensures that the ratio of diastereoisomeric pairs is 60:40 in favour of the desired R, S and S, R pair. This ensures a reduction in the number of recrystallisation steps that are required to remove the R, R/S, S pair.
Based on information provided herein, one of ordinary skill in the art can readily determine a solvent that is suitable for use in the invention. While acetone is exemplified, other solvents that may be found suitable include esters, e.g. of acetic acid such as ethyl acetate, and other ketones such as methyl isobutyl ketone (MEK). In the given formulae, R1 and R2 are preferably C1-4 alkyl, and R1 is preferably methyl. A higher ketone than acetone is preferred for the recrystallisation.
Impurities are efficiently reduced by carrying out the methylation reaction in acetone compared to MEK. Sequential recrystallisations from MEK/methanol systematically eliminate these impurities alongside the R, R/S, S pair of diastereoisomers.
The overall yield of glycopyrronium bromide as a product of the methylation reaction and subsequent purification steps is typically 20-30%. Additional recrystallisation steps can be added should the material from the any given recrystallisation not meet the preferred specification of not more than 0.2% R, R/S, S.
The following Example (stage 3 of the 3-stage process shown above) illustrates the invention. “Cold” means a temperature of 0-10° C.
A solution of crude glycopyrronium base (13.0 kg; 42.8 mol) in acetone (130 L) is treated with methyl bromide gas (4.5 kg; 47.4 mol) over 30 minutes while maintaining a temperature between −5° C. and 5° C. The mixture is then warmed to between 15° C. and 25° C. and maintained at this temperature for 2 hours to ensure complete crystallisation of the glycopyrronium bromide has taken place. The product is filtered by centrifugation, washed with cold acetone (40-60 L) and collected (15 kg).
The material (15 kg) is dissolved at reflux in a mixture of methanol (13.0 L) and MEK (90 L). Additional MEK (135 L) is added and reflux (75-85° C.) maintained for 30 minutes. The mixture is then cooled to between −10° C. and 0° C. at a rate of 30° C./hour, allowing controlled crystallisation of a purified product which is filtered by centrifugation, washed with cold MEK (30-50 L) and collected (7 kg). The purity of the product from this first recrystallisation is typically not less than 99% and the diastereoisomeric purity is typically 94-95% (by HPLC).
The material (7 kg) is dissolved at reflux in a mixture of methanol (10.2 L) and MEK (45 L). Additional MEK (65 L) is added and reflux (75-85° C.) maintained for 30 minutes. The mixture is then cooled to between −10° C. and 0° C. at a rate of 30° C./hour, allowing controlled crystallisation of a purified product which is filtered by centrifugation, washed with cold MEK (20-30 L) and the product collected (5.3 kg). The purity of the product from this recrystallisation is typically not less than 99.9% and the diastereoisomeric purity is typically not less than 99.5% (by HPLC).
The material (5.3 kg) is dissolved at reflux in a mixture of methanol (4.2 L) and MEK (33 L). Additional MEK (47 L) is added and reflux (75-85° C.) maintained for 30 minutes. The mixture is then cooled to between −10° C. and 0° C. at a rate of 30° C./hour allowing controlled crystallisation of a purified product that is filtered, washed with cold MEK (20 L) and oven dried. The drug substance is a fine white crystalline solid (4.9 kg). The purity of the product from this first recrystallisation is typically not less than 99.95% and the diastereoisomeric purity is typically not less than 99.8% (by HPLC).
This method uses a Waters Alliance 2695 HPLC system with a PDA 996 detector, column oven and Waters Empower data system or equivalent:
Column: Astec Cyclobond I 2000; 250 mm×4.6 mm ID
Temperature: 15° C.
Injection Volume: 20 μL
Detection: UV at 230 nM
Run Time: 20 min
Mobile Phase: 1.0 M triethyl ammonium acetate buffer solution (5.0 ml) mixed with acetonitrile (750 ml) and HPLC water (245 ml)
Flow Rate: 1.0 ml/min
Gradient: Isocratic
Run times and relative response times for R, S/S, R glycopyrronium bromide (the drug substance) and the R, R/S, S impurity are as follows:
The method has a limit of detection of 0.03% and a limit of quantification of 0.1%. The process as described is capable of reproducing a drug substance with not more than 0.2% of the R, R/S, S pair.
A HPLC method has been developed and validated providing an in-process check and test method to control levels of this impurity to <0.2% in batches of the drug substance. Due to the efficiency of the crystallization required to meet this specification, all other impurities are eliminated. Impurities carried through from impure MCPM can readily be eliminated in the recrystallisation steps.
This Example validates the purification procedure, demonstrating that even poor quality MCPM can be processed to drug substance of excellent quality. The elimination of these impurities is apparently the consequence of controlled recrystallisation. Uncontrolled crystallization leads to an impure product with an inconsistent particle size distribution. It was surprising to find the controlled cooling rate employed not only defined a high level of purity but also provided control of particle size distribution and uniform morphological habit, as shown by imaging. Subsequent micronisation of this product has provided a physically stable drug substance that is suitable for formulation into a drug product optimized for inhaled delivery.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0504463.1 | Mar 2005 | GB | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/GB06/00770 | 3/3/2006 | WO | 00 | 5/12/2008 |
